A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines.

IF 5.5 3区 医学 Q1 IMMUNOLOGY Expert Review of Vaccines Pub Date : 2024-09-13 DOI:10.1080/14760584.2024.2402955
Mary Bausch-Jurken,Rachel S Dawson,Francesca Ceddia,Veronica Urdaneta,Morgan A Marks,Yohei Doi
{"title":"A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines.","authors":"Mary Bausch-Jurken,Rachel S Dawson,Francesca Ceddia,Veronica Urdaneta,Morgan A Marks,Yohei Doi","doi":"10.1080/14760584.2024.2402955","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\r\nSince the original COVID-19 vaccines were developed, abundant clinical trial and real-world evidence evaluating the efficacy, effectiveness, and safety of COVID-19 vaccines has been collected. Knowledge of the relative benefits and risks of COVID-19 vaccines is essential for building trust within target populations, ensuring they remain effectively and safely protected against an enduring infectious threat.\r\n\r\nAREAS COVERED\r\nThis descriptive review discusses the benefits and risks associated with marketed Moderna, Inc. mRNA-based COVID-19 vaccines, focusing on their real-world effectiveness and safety profiles in various age groups. Adverse events of interest and potential benefits of vaccination are reviewed, including reduced risk for severe COVID-19 and long-term health outcomes, reduced economic and societal costs, and reduced risk for SARS-CoV-2 transmission.\r\n\r\nEXPERT OPINION\r\nPost-marketing safety and real-world data for Moderna, Inc. COVID-19 mRNA vaccines strongly support a positive benefit - risk profile favoring vaccination across all age groups. Although COVID-19 is no longer considered a global health pandemic, health risks associated with SARS-CoV-2 infection remain high. Concerted efforts are required to engage communities and maintain protection through vaccination. Continued surveillance of emerging variants and monitoring of vaccine safety and effectiveness are crucial for ensuring sustained protection against SARS-CoV-2.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"81 5 1","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2402955","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

INTRODUCTION Since the original COVID-19 vaccines were developed, abundant clinical trial and real-world evidence evaluating the efficacy, effectiveness, and safety of COVID-19 vaccines has been collected. Knowledge of the relative benefits and risks of COVID-19 vaccines is essential for building trust within target populations, ensuring they remain effectively and safely protected against an enduring infectious threat. AREAS COVERED This descriptive review discusses the benefits and risks associated with marketed Moderna, Inc. mRNA-based COVID-19 vaccines, focusing on their real-world effectiveness and safety profiles in various age groups. Adverse events of interest and potential benefits of vaccination are reviewed, including reduced risk for severe COVID-19 and long-term health outcomes, reduced economic and societal costs, and reduced risk for SARS-CoV-2 transmission. EXPERT OPINION Post-marketing safety and real-world data for Moderna, Inc. COVID-19 mRNA vaccines strongly support a positive benefit - risk profile favoring vaccination across all age groups. Although COVID-19 is no longer considered a global health pandemic, health risks associated with SARS-CoV-2 infection remain high. Concerted efforts are required to engage communities and maintain protection through vaccination. Continued surveillance of emerging variants and monitoring of vaccine safety and effectiveness are crucial for ensuring sustained protection against SARS-CoV-2.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于 Moderna, inc.COVID-19 疫苗的实际影响的描述性综述。
简介自最初开发 COVID-19 疫苗以来,已经收集了大量临床试验和真实世界的证据来评估 COVID-19 疫苗的效力、有效性和安全性。了解 COVID-19 疫苗的相对益处和风险对于在目标人群中建立信任至关重要,可确保他们得到有效、安全的保护,免受持久的传染病威胁。 本描述性综述讨论了与已上市的 Moderna 公司基于 mRNA 的 COVID-19 疫苗相关的益处和风险,重点关注其在不同年龄段的实际有效性和安全性。专家意见:Moderna, Inc. COVID-19 mRNA 疫苗上市后的安全性和真实世界数据表明,该疫苗可降低严重 COVID-19 和长期健康后果的风险,降低经济和社会成本,并降低 SARS-CoV-2 传播的风险。COVID-19 mRNA 疫苗上市后的安全性和真实世界数据有力地证明了接种疫苗对所有年龄组都有积极的收益-风险分析。尽管 COVID-19 已不再被认为是全球健康大流行病,但与 SARS-CoV-2 感染相关的健康风险仍然很高。需要共同努力让社区参与进来,并通过接种疫苗保持保护。对新出现的变种进行持续监测以及对疫苗的安全性和有效性进行监控,对于确保持续预防 SARS-CoV-2 至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Vaccines
Expert Review of Vaccines 医学-免疫学
CiteScore
9.10
自引率
3.20%
发文量
136
审稿时长
4-8 weeks
期刊介绍: Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
期刊最新文献
Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the omicron BA.2.86/JN.1 period among older adults in seven European countries: a VEBIS-EHR network study. Adult vaccination in three Eastern Mediterranean countries: current status, challenges and the way forward. Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomized clinical trial. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines. Estimating the time required to reach HPV vaccination targets across Europe.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1